Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 5/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31596380 | 0.98 | MAPT (0.57) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL2674802 | 0.92 | HTR2B (0.55) | POLBMAPTHTR2BNPY5RKMT2A | |
| SCHEMBL6756134 | 0.92 | NPC1 (0.59) | POLBMAPTHTR2BNPY5RKMT2A | |
| SCHEMBL2640467 | 0.91 | HTR2B (0.57) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL6753945 | 0.91 | TRPC3 (0.55) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL6757201 | 0.91 | NPC1 (0.62) | POLBMAPTHTR2BNPY5RKDM4E | |
| SCHEMBL724921 | 0.91 | NPC1 (0.62) | POLBMAPTHTR2BNPY5RKDM4E | |
| Ammonia Solution, Strong SCHEMBL5028354 | 0.90 | TRPC3 (0.54) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL2640300 | 0.90 | PARP1 (0.56) | ALDH1A1POLBMAPTHPGDTSHR | |
| SCHEMBL2106423 | 0.89 | HTR2B (0.52) | ALDH1A1POLBMAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250837-B | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin by thermal curing of solvent-free anhydride | 南京先进生物材料与过程装备研究院有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-112250837-A | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin through solvent-free anhydride thermosetting | 南京先进生物材料与过程装备研究院有限公司 | 2021-01-22 | — | — | CN | claimed |
| CN-116535300-B | Method for catalyzing 5-chloro-2-pentanone to generate cyclopropyl methyl ketone by eutectic solvent | 中国科学院山西煤炭化学研究所 | 2024-12-20 | — | — | CN | disclosed |
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| CN-116535300-A | Method for catalyzing 5-chloro-2-pentanone to generate cyclopropyl methyl ketone by eutectic solvent | 中国科学院山西煤炭化学研究所 | 2023-08-04 | — | — | CN | disclosed |
| CN-112250837-B | Bio-based furan epoxy resin and method for preparing bio-based furan epoxy resin by thermal curing of solvent-free anhydride | 南京先进生物材料与过程装备研究院有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115850039-A | Method for synthesizing cyclopropyl methyl ketone through imine intermediate | 江苏中旗科技股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210371992-A1 | ELECTROCHEMICAL ORGANIC REACTION SETUP AND METHODS | PIRAMAL PHARMA LIMITED (IN) | 2021-12-02 | — | — | US | disclosed |
| US-6720329-B2 | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-04-13 | — | — | US | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003024899-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1095025-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001704-A2 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | ALDH1A1 1051/4885POLB 885/4885MAPT 4213/4885 |
| US-20030087882-A1 | Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, TIMP3 | ALDH1A1 750/4885POLB 1005/4885MAPT 3924/4885 |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | ALDH1A1 3630/4885POLB 597/4885MAPT 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.